Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 15 clinical trials
Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation (GO-GUT)

The hypothesis of the study is that the presence of (subclinical) gut inflammation at baseline in patients with early active axial spondyloarthritis predisposes to a more severe disease defined as more need to use anti-tumor necrosis factor therapy and a shorter time to relapse after stopping anti-tumor necrosis factor therapy …

factor a
golimumab
tumor necrosis factor
back pain
remission
  • 3 views
  • 03 Feb, 2022
  • 3 locations
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis (AFFINITY)

The purpose of this study is to evaluate the efficacy of guselkumab plus golimumab combination treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) to a

tumour necrosis
rheumatoid nodules
peripheral arthritis
adalimumab
arthritis mutilans
  • 7 views
  • 25 Jul, 2022
  • 16 locations
Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis (ROC-SPA)

rheumatoid arthritis. Etanercept is a fusion protein with TNF receptor type II p75 and IgG1 Fc fragment, whereas adalimumab, infliximab, and golimumab are monoclonal antibodies. Certolizumab is a fusion

steroidal anti-inflammatory drugs
biological therapy
monoclonal antibodies
secukinumab
tumor necrosis factor
  • 17 views
  • 27 Feb, 2022
  • 13 locations
A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (PURSUIT 2)

The purpose of this study is to evaluate efficacy of golimumab in inducing clinical remission as assessed by the Mayo score, in pediatric participants with moderately to severely active

azathioprine
endoscopy
sigmoidoscopy or colonoscopy
mercaptopurine
methotrexate
  • 53 views
  • 11 Jul, 2022
  • 50 locations
  • 0 views
  • 20 Sep, 2022
  • 3 locations
Golimumab for the Treatment of Refractory Behcet's Uveitis

The aim of this single-center prospective study is to evaluate the efficacy and safety of Golimumab (GOL), fully humanized anti-tumor necrosis factor (TNF)-α monoclonal antibody, in the

immunosuppressant
monoclonal antibody
uveitis
panuveitis
prednisolone acetate ophthalmic suspension
  • 31 views
  • 16 May, 2022
  • 1 location
Identification of Predictive Biomarkers for Response to Biologic Therapies in Inflammatory Bowel Disease

Prospective, multicentre trial which the biologic treatment will be initiated by clinical indication. The treatment selection anti-TNF (infliximab, adalimumab or golimumab), vedolizumab and

adalimumab
tumor necrosis factor alpha
luminal
intestinal diseases
inflammatory bowel disease
  • 32 views
  • 03 Sep, 2021
  • 19 locations
EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis (EFFICACI)

infliximab, adalimumab and golimumab) revolutionized the management of immune-mediated chronic diseases in the past two decades. However, about one third of patients will not respond to a first anti

tumour necrosis
janus kinase inhibitor
intestinal diseases
steroid therapy
tumor necrosis factor
  • 22 views
  • 16 Feb, 2022
  • 15 locations
Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events

Post-authorization, prospective and unicenter clinical trial, in which patients with UC will be included. The treatment with anti-TNFα (infliximab, adalimumab or golimumab) or JAK-inhibitors

golimumab
adalimumab
vedolizumab
Accepts healthy volunteers
infliximab
  • 0 views
  • 20 Aug, 2022
  • 1 location
Assessing Patient Confidence in Biologic Medications

cycle. Examples of biologic medications commonly used in dermatology include tumor necrosis factor-alpha (TNF-alpha), blockers/inhibitors (etanercept, infliximab, certolizumab pegol, golimumab

tumor necrosis factor alpha
ixekizumab
certolizumab pegol
etanercept
secukinumab
  • 67 views
  • 25 Apr, 2022
  • 1 location